BioSpace News Archive

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering.

Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of an underwritten public offering of 16,428,571 shares of its common stock, offered at a price of $1.75 to the public,

First patient injected in phase I trial evaluating tumor-agnostic NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer

Maravai LifeSciences , Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2020 financial and operating results after the market closes on Tuesday, March 2, 2021, and will host a conference call on the same day at 2:00 pm. PT/ 5:00 p.m. ET. To participate in the conference call, dial (833) 693-0536 or (661) 407-1576 and

On Tuesday, January 26th, Governor Andy Beshear’s office announced that the first two cases of a more contagious variant of coronavirus, first identified in the United Kingdom, have been confirmed in Kentucky.

Growing population and prevalent unhealthy eating habits have driven nutrigenomics testing market trends substantially over the past few years.

The pH meters market growth is a result of the growing incidences of food adulteration in developing as well as developed countries.

A look at the latest advancements in the global rat model market unveils a study that examined the possible therapeutic methods for humans dealing with opioid addiction.

Growing cases of influenza and chronic disorders such as diabetes and cardiovascular diseases will fuel rapid influenza diagnostic tests (RIDT) market share in the coming years.

Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it has commenced an underwritten public offering of its common stock